Ironwood Pharmaceuticals INC (IRWD) Shareholder Ecor1 Capital LLC Has Lifted Stake

Lawrence Kim
December 19, 2017

CONE's SI was 6.43M shares in December as released by FINRA. Its up 0.03% from 6.43M shares previously. The stock increased 1.11% or $0.175 during the last trading session, reaching $15.895. About 193,293 shares traded. Zumiez Inc. (NASDAQ:ZUMZ) has risen 3.10% since December 18, 2016 and is uptrending. It has underperformed by 3.04% the S&P500. Analysts anticipate that Ironwood Pharmaceuticals, Inc. will post ($0.91) earnings per share for the current year. The Maryland-based Brown Capital Management Llc has invested 1.44% in the stock. The company has market cap of $2.37 billion. Credit Suisse Group assumed coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, November 27th. Two Sigma Securities Ltd Llc reported 0.04% of its portfolio in Ironwood Pharmaceuticals, Inc. It has outperformed by 40.70% the S&P500. Pacad Investment Ltd. acquired a new position in Ironwood Pharmaceuticals during the fourth quarter worth approximately $171,000.

The company's consensus rating on Reuter's scale remained unchanged from 1.33 to 1.33 during a month. The Company's clients operate in various industries, including information technology, financial services, energy, gas and oil, mining, medical, and consumer goods and services.

The stock increased 5.22% or $1.05 during the last trading session, reaching $21.15. Out of 4 Wall Street analysts rating Ironwood Pharma, 1 give it "Buy", 0 "Sell" rating, while 3 recommend "Hold". It turned negative, as 24 investors sold IMMU shares while 30 reduced holdings. 47 funds opened positions while 113 raised stakes. The North Carolina-based Bancorp Of America De has invested 0% in Immunomedics, Inc.

Ecor1 Capital Llc increased its stake in Ironwood Pharmaceuticals Inc (IRWD) by 29.19% based on its latest 2017Q2 regulatory filing with the SEC. Smith Asset Management Group Limited Partnership has invested 0.02% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:CONE) for 146,674 shares. Strs Ohio now owns 10,600 shares of the biotechnology company's stock worth $200,000 after purchasing an additional 4,100 shares in the last quarter. Meeder Asset Mngmt Incorporated holds 115 shares. Duff Phelps Investment Mgmt accumulated 452,102 shares. 12,161 are owned by Raymond James Fincl Serv Advsr. Manufacturers Life Insurance The has 118,839 shares. Pitcairn invested in 3,707 shares or 0.02% of the stock. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.07.

Among 4 analysts covering Clearwater Paper (NYSE:CLW), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. The rating was maintained by Jefferies on Friday, June 9 with "Buy". The rating was maintained by Cowen & Co on Wednesday, November 1 with "Buy". Ecor1 Capital Llc who had been investing in Ironwood Pharmaceuticals Inc for a number of months, seems to be bullish on the $2.38B market cap company. The stock has "Hold" rating by Zacks on Monday, August 10. The stock of Immunomedics, Inc. The rating was downgraded by DA Davidson on Thursday, May 12 to "Neutral". Mizuho has "Buy" rating and $2200 target. (NASDAQ:CONE) earned "Buy" rating by SunTrust on Wednesday, December 6. During the same quarter past year, the firm posted ($0.18) EPS. The SI to Ironwood Pharmaceuticals Class A's float is 12.6%.

Since August 18, 2017, it had 0 insider buys, and 3 selling transactions for $59,508 activity. The insider OLANOFF LAWRENCE S sold $32,300. (NASDAQ:IRWD) on Tuesday, September 5. $2,968 worth of stock was sold by Consylman Gina on Friday, August 18. The firm has "Buy" rating given on Friday, August 5 by Jefferies. (NASDAQ:IRWD) to report earnings on February, 20. Ironwood Pharmaceuticals had 35 analyst reports since August 6, 2015 according to SRatingsIntel. Wedbush maintained the stock with "Neutral" rating in Friday, February 19 report. JP Morgan downgraded Ironwood Pharmaceuticals, Inc. Piper Jaffray upgraded the stock to "Overweight" rating in Friday, October 14 report. (NASDAQ:IRWD) has "Hold" rating given on Tuesday, September 27 by WallachBeth Capital. The company was maintained on Thursday, April 28 by Wedbush. They set a buy rating and a $19.00 target price for the company. The rating was maintained by Cowen & Co on Thursday, July 20 with "Buy".

Short interest is another tool that analysts use to gauge investor sentiment. Its down 0.06, from 1.31 in 2017Q1.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Nationwide Fund Advsr reported 280,394 shares. Wells Fargo & Com Mn holds 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Tortoise Inv accumulated 3,293 shares. (NASDAQ:IRWD). Orbimed Advisors Limited Liability Corporation owns 5.76M shares. California Public Employees Retirement System grew its holdings in shares of Ironwood Pharmaceuticals by 7.1% during the third quarter. (NASDAQ:IRWD). Teachers Retirement System Of The State Of Kentucky reported 0.1% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Goldman Sachs Grp Inc reported 798,457 shares. Millennium Ltd Liability owns 0% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Wellington Management Group Inc Llp holds 18.74M shares. Blue Jay Capital Management Llc owns 470,000 shares or 6.05% of their USA portfolio. Bancshares Of Montreal Can holds 0% or 66,587 shares.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article